VT · State regulatory reference

Vermont.

Moderate

Vermont permits establishing a provider-patient relationship and prescribing via telemedicine: under 18 V.S.A. § 9361(b) a Vermont-licensed provider may prescribe after 'an appropriate examination of the patient in person, through telemedicine, or by the use of instrumentation,' held to the in-person standard of care with no mandatory prior in-person visit. Compounding under the Board of Pharmacy's Rule 10-4 (effective Feb. 1, 2026) adopts USP <795>/<797>/<800> and 21 U.S.C. § 353a (503A) with no GLP-1/semaglutide-specific rule. The distinctive friction is licensing, not prescribing: Vermont's telehealth-license regime (26 V.S.A. § 3054) caps an out-of-state provider without a full Vermont license to 20 unique Vermont patients over a two-year term. No Vermont board enforcement specific to peptide/GLP-1 compounding was found.

Last reviewed · 2026-05-25 · verified entry

Agencies

Medical board

Vermont Medical Board

https://sos.vermont.gov/medical-practice/ ↗

Pharmacy board

Vermont Board of Pharmacy

https://sos.vermont.gov/pharmacy/ ↗

TPC notes

Telehealth

18 V.S.A. § 9361(b) allows an initial exam and prescribing via synchronous telemedicine with no prior in-person requirement, held to the in-person standard of care with documented informed consent (§ 9361(c)); out-of-state providers must hold a Vermont telehealth license/registration (26 V.S.A. § 3054, capped at 20 patients over two years) or full license.

Compounding

Board of Pharmacy Rule 10-4 (eff. Feb. 1, 2026) requires registration as a compounding pharmacy and compliance with USP <795>/<797>/<800> and 21 U.S.C. § 353a, tied to a patient-specific practitioner order; there is no Vermont-specific GLP-1/semaglutide compounding restriction beyond federal 503A.

Sources